Create Account | Sign In: Author or Forum

Search Symptoms

Category: Family Medicine | Gynecology | Internal Medicine | Oncology | Radiology | Journal

Back to Journal Articles

Study IDs Which Women Benefit From DBT Versus Digital Mammography

Last Updated: July 30, 2020.

Improvements in recall rates and cancer detection rates with digital breast tomosynthesis versus digital mammography are greatest on baseline examinations, according to a study published online July 28 in JAMA Network Open.

THURSDAY, July 30, 2020 (HealthDay News) -- Improvements in recall rates and cancer detection rates with digital breast tomosynthesis (DBT) versus digital mammography (DM) are greatest on baseline examinations, according to a study published online July 28 in JAMA Network Open.

Kathryn P. Lowry, M.D., from the University of Washington in Seattle, and colleagues compared DM and DBT performance in a study with 1,584,079 screening examinations of women aged 40 to 79 years undergoing screening mammography at 46 facilities from January 2010 to April 2018.

The researchers found that the adjusted differences in DM versus DBT performance were largest on baseline examinations; for example, for women aged 50 to 59 years, per 1,000 baseline examinations, recall rates decreased from 241 examinations for DM to 204 for DBT (relative risk, 0.84), while cancer detection rates increased from 5.9 to 8.8 (relative risk, 1.50). Women aged 40 to 79 years with heterogeneously dense breasts had improved recall rates and improved cancer detection on subsequent examinations; among women aged 50 to 59 years, the number of recall examinations decreased from 102 to 93 per 1,000 examinations with DM and DBT, respectively (relative risk, 0.91), while cancer detection increased from 3.7 to 5.3 (relative risk, 1.42). No improvements in recall or cancer detection were seen for women with extremely dense breasts.

"Our results provide guidance for women and physicians making decisions regarding use of DBT for routine screening," the authors write.

Several authors disclosed financial ties to the biopharmaceutical and medical technology industries.

Abstract/Full Text
Editorial


Previous: ACS Issues Updated Guideline for Cervical Cancer Screening Next: P-tau217 Shows Promise as Biomarker for Alzheimer Disease

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion: